Discovery of Plasmepsin Inhibitors by Fragment-Based Docking and Consensus Scoring

被引:44
|
作者
Friedman, Ran [1 ]
Caflisch, Amedeo [1 ]
机构
[1] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland
关键词
antiplasmodial agents; drug discovery; high-throughput docking; malaria; molecular dynamics; HIGH-THROUGHPUT DOCKING; MOLECULAR-DYNAMICS; FORCE-FIELD; ELECTROSTATIC SOLVATION; PLASMODIUM-FALCIPARUM; KINASE INHIBITORS; AQUEOUS-SOLUTIONS; BETA-SECRETASE; ENERGY; MALARIA;
D O I
10.1002/cmdc.200900078
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria. We have discovered six inhibitors of PM II by high-throughput fragment-based docking of a diversity set of similar to 40000 molecules, and consensus:scoring with force field energy functions. Using the common scaffold of the three most active inhibitors (IC50 = 2-5 mu m), another seven inhibitors were identified by substructure search. Furthermore, these 13 inhibitors belong to at least three different classes of compounds. The in silico approach was very effective since a total of 13 active compounds were discovered by testing only 59 molecules in an enzymatic assay. This hit rate is about one to two orders of magnitude higher than those reported for medium- and high-throughput screening techniques in vitro. Interestingly, one of the inhibitors identified by docking was halofantrine, an antimalarial drug of unknown mechanism. Explicit water molecular dynamics simulations were used to discriminate between two putative binding modes of halofantrine in PM II.
引用
收藏
页码:1317 / 1326
页数:10
相关论文
共 50 条
  • [21] Fragment-based lead discovery
    David C. Rees
    Miles Congreve,
    Christopher W. Murray
    Robin Carr
    Nature Reviews Drug Discovery, 2004, 3 : 660 - 672
  • [22] Capitalizing on Fragment-Based Discovery
    Liszewski, Kathy
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2009, 29 (08): : 18 - +
  • [23] Fragment-based drug discovery
    Erlanson, DA
    McDowell, RS
    O'Brien, T
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) : 3463 - 3482
  • [24] Fragment-Based Lead Discovery
    Davis, Ben J.
    Roughley, Stephen D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 50: PLATFORM TECHNOLOGIES IN DRUG DISCOVERY AND VALIDATION, 2017, 50 : 371 - 439
  • [25] Fragment-based drug discovery
    Wendy A. Warr
    Journal of Computer-Aided Molecular Design, 2009, 23 : 453 - 458
  • [26] Fragment-Based Lead Discovery
    Congreve, Miles
    Murray, Christopher W.
    Carr, Robin
    Rees, David C.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 431 - 448
  • [27] fragment-based ligand discovery
    Fischer, Marcus
    Hubbard, Roderick E.
    MOLECULAR INTERVENTIONS, 2009, 9 (01) : 22 - 30
  • [28] Fragment-based drug discovery
    Warr, Wendy A.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2009, 23 (08) : 453 - 458
  • [29] Fragment-Based Drug Discovery
    Norton, Raymond S.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2013, 66 (12) : 1463 - 1464
  • [30] Fragment-based discovery in spotlight
    Lipp, Elizabeth
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2007, 27 (19): : 22 - +